Daihan Scientific Co., Ltd

As of March 31, 2026, Daihan Scientific Co., Ltd carries a market capitalization of 33.54B, placing it among publicly traded companies globally. Its enterprise value stands at 30.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Daihan Scientific Co., Ltd has 7.45M shares outstanding.

As of March 31, 2026, Daihan Scientific Co., Ltd trades at a trailing price-to-earnings ratio of 9.53. The price-to-sales ratio is 0.38, and the price-to-book ratio stands at 0.75.

As of March 31, 2026, Daihan Scientific Co., Ltd trades at an EV/EBITDA multiple of 4.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Daihan Scientific Co., Ltd trades at an EV/FCF ratio of 4.78, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 30.34B versus a market cap of 33.54B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Daihan Scientific Co., Ltd maintains a current ratio of 3.89, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Daihan Scientific Co., Ltd posted a return on equity (ROE) of 7.61, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.28 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.08, useful for judging operating efficiency across full business cycles. The company generates approximately 706.49M in revenue per employee across its workforce of 117.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.26 indicates how many times Daihan Scientific Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Daihan Scientific Co., Ltd recorded 887.09M in income tax expense. That works out to an effective tax rate of 15.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.76B, leaving 3.31B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Daihan Scientific Co., Ltd's stock has declined approximately 24.01% over the past 52 weeks. The 50-day moving average sits at 3,607.90, while the 200-day moving average is 4,157.73.

Over the twelve months ended March 31, 2026, Daihan Scientific Co., Ltd generated 83.01B in revenue and converted that into 3.31B in net income, yielding earnings per share of 695.38. EBITDA reached 7.33B, while operating income came in at 5.58B.

As of March 31, 2026, Daihan Scientific Co., Ltd holds 16.19B in cash and equivalents against 1.10B in total debt, resulting in a net debt position of -3.10B. Total book value stands at 44.66B, with working capital of 38.21B providing operational flexibility.

Daihan Scientific Co., Ltd produced 6.77B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -425.89M in capital expenditures, free cash flow totaled 6.34B - equivalent to 904.99 per share.

Over the twelve months ended March 31, 2026, Daihan Scientific Co., Ltd posted a gross margin of 27.64, reflecting its pricing power and cost economics. The operating margin of 6.72 and net profit margin of 3.98 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Daihan Scientific Co., Ltd paid dividends of 106.16 per share. The dividend payout ratio of 11.56 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 20.11, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Daihan Scientific Co., Ltd shareholders.

Daihan Scientific Co., Ltd's most recent stock split took place on December 29, 2014 with a 100:107 split ratio.

As of March 31, 2026, Daihan Scientific Co., Ltd has an Altman Z-Score of 4.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.